Shionogi & Co., Ltd. (SGIOY) Stock Price, News & Analysis

Company Overview

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Key Stats

• Today's Range: $6.57 to $6.79
• 50-Day Range: $6.59 to $11.25
• 52-Week Range: $6.22 to $9.11
• Volume: 241,509 shs
• Average Volume: 255,328 shs
• Market Capitalization: $12.01 billion
• P/E Ratio: 11.51
• Dividend Yield: 1.78%
• Price Target: N/A
• Consensus Rating: N/A

SGIOY Stock Analysis - Frequently Asked Questions

How have SGIOY shares performed this year?

Shionogi & Co., Ltd.'s stock was trading at $11.9720 at the beginning of the year. Since then, SGIOY stock has decreased by 43.6% and is now trading at $6.75.
View the best growth stocks for 2024 here.

How were Shionogi & Co., Ltd.'s earnings last quarter?

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) posted its quarterly earnings results on Wednesday, January, 31st. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.33 by $0.11. The firm had revenue of $719.72 million for the quarter. Shionogi & Co., Ltd. had a trailing twelve-month return on equity of 11.95% and a net margin of 35.53%.

How do I buy shares of Shionogi & Co., Ltd.?

Shares of SGIOY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 1/31/2024
• Today: 11/23/2024
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Private households
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:SGIOY
• CUSIP: N/A
• CIK: 1281721
• Web: www.shionogi.co.jp
• Phone: (166) 202-2161
• Fax: N/A
• Employees: 5,680
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.5867
• Trailing P/E Ratio: 11.51
• Forward P/E Ratio: 25.00
• P/E Growth: 4.5
• Net Income: $1.12 billion
• Net Margins: 35.53%
• Pretax Margin: 45.57%
• Return on Equity: 11.95%
• Return on Assets: 10.56%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 5.86
• Quick Ratio: 5.37

Sales & Book Value

• Annual Sales: $3.01 billion
• Price / Sales: 3.99
• Cash Flow: $0.71 per share
• Price / Cash Flow: 9.46
• Book Value: $4.86 per share
• Price / Book: 1.39

Miscellaneous

• Outstanding Shares: 1,779,260,000
• Free Float: N/A
• Market Cap: $12.01 billion
• Optionable: Not Optionable
• Beta: 0.22